Key result
Concurrent AF linked to ~86% higher in-hospital mortality in multiple myeloma.
Why the study?
The clinical significance and outcomes of concurrent atrial fibrillation in hospitalized multiple myeloma patients remain understudied.
Does concurrent atrial fibrillation increase in-hospital mortality in patients hospitalized for multiple myeloma?
Observational (n=148,030)
Yes
Does concurrent atrial fibrillation increase in-hospital mortality in patients hospitalized for multiple myeloma?
In hospitalized multiple myeloma patients, the presence of atrial fibrillation is independently associated with substantially elevated in-hospital mortality risk, prolonged length of stay, and increased costs.
AF signals higher in-hospital mortality risk in multiple myeloma; extends observational data but leaves open whether interventions alter outcomes.
Background Atrial fibrillation (AF) and multiple myeloma (MM) represent two prevalent chronic diseases with overlapping risk factors in aging populations. However, the clinical significance and outcomes of concurrent AF in MM hospitalizations remain understudied. We aimed to determine the prevalence of AF in hospitalized MM patients and quantify its independent association with in-hospital mortality, length of stay (LOS), and hospital charges. Methods We analyzed 148,030 weighted adult (≥18 years) discharges with principal diagnosis MM from the National Inpatient Sample (2016–2022). The primary outcome was in-hospital mortality. Secondary outcomes were LOS and total hospital charges. Survey-weighted multivariable logistic and linear regression models adjusted for age, sex, race, payer, income, hospital characteristics, admission type, Charlson comorbidity index, and calendar year. Results AF was present in 13.6% of MM hospitalizations (n=20,079 weighted). Compared to MM without AF, patients with AF were older (71.9 vs. 64.5 years; p<0.001) and had higher charlson scores (4.39 vs. 3.60; p<0.001). Crude in-hospital mortality was 8.8% with AF versus 4.1% without AF. In adjusted logistic regression, AF remained independently associated with 86% higher odds of in-hospital mortality (adjusted OR 1.86; 95% CI 1.62–2.14; p<0.001). AF was also independently associated with 1.84 additional hospital days (95% CI 1.45–2.23; p<0.001) and $28,749 higher hospital charges (95% CI $21,158–$36,341; p<0.001) after full adjustment. Conclusion Atrial fibrillation affects one in seven MM hospitalizations and independently confers substantially elevated mortality risk, prolonged LOS, and markedly increased costs, even after controlling for age and comorbidity burden. These findings identify AF as a high-impact cardio-oncologic phenotype in MM and identify the need for integrated cardiovascular risk stratification and management in this population.
No takes yet. Share an insight, caveat, or question.
Bolad et al. (2026) conducted an observational in Multiple myeloma (n=148,030). Atrial fibrillation vs. Without atrial fibrillation was evaluated on In-hospital mortality (OR 1.86, 95% CI 1.62-2.14, p=<0.001). Concurrent atrial fibrillation in multiple myeloma hospitalizations was independently associated with an 86% higher odds of in-hospital mortality (adjusted OR 1.86; 95% CI 1.62-2.14; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: